Köse Sükran, Türken Melda, Cavdar Gülsün, Tatar Bengü, Senger Süheyla Serin
Izmir Tepecik Education and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Izmir, Turkey.
Hum Vaccin. 2010 Nov;6(11):903-5. doi: 10.4161/hv.6.11.12918. Epub 2010 Nov 1.
Hepatitis B infection is one of the infectious diseases quite common in Turkey and around the world. Hepatitis B virus infection is a significant health problem which may cause chronic hepatitis, cirrhosis and hepatocellular carcinoma. With the introduction of Hepatitis B vaccine, a significant progress has been made in the prevention of HBV infections. The purpose of the study was to evaluate the characteristics of the individuals included in the risk group who admitted to our vaccination clinic, as well as their immune responses following the vaccination. Among the patients admitted to the vaccination clinic of our hospital between January 2003-December 2005 and that were included in the risk group (patients who have family members with chronic Hepatitis B infection, healthcare workers, hemodialysis patients etc.), those who were included in the vaccination program by examining the results of HBs Ag, anti-HBc and anti-HBs were evaluated in terms of their characteristics (age, gender, smoking etc.) and results of Anti-HBs score. A total of 958 people were included in the vaccination program. Upon evaluation in terms of risk factors, presence of patients with chronic hepatitis B infection in the family was found to be 80.6% (772/958), being healthcare worker was 9.2% (88/958), HCV positivity and chronic liver disease was 3.0% (29/958), being a hemodialysis patient was 2.8% (27/958), and being an oncology patient was 2.1% (20/958). Post-vaccination immune response could be evaluated in 69.8% (669/958) of patients and no responsiveness to vaccine was detected only in 8.1% (54/669) of them. Of the non-responders, 64.8% (35/54) were hemodialysis and oncology patients. Anti-HBs positivity rate following hepatitis B vaccination program was found compatible with the results of previous studies. With this vaccine of considerably high effectiveness, immunization of the entire community including primarily the risk groups should be targeted.
乙型肝炎感染是土耳其及全球较为常见的传染病之一。乙型肝炎病毒感染是一个重大的健康问题，可能导致慢性肝炎、肝硬化和肝细胞癌。随着乙肝疫苗的引入，在预防乙肝病毒感染方面取得了重大进展。本研究的目的是评估进入我们疫苗接种诊所的风险人群的特征，以及他们接种疫苗后的免疫反应。在2003年1月至2005年12月期间进入我院疫苗接种诊所并被纳入风险组的患者（有慢性乙型肝炎感染家庭成员的患者、医护人员、血液透析患者等）中，通过检测乙肝表面抗原（HBs Ag）、乙肝核心抗体（抗-HBc）和乙肝表面抗体（抗-HBs）的结果而被纳入疫苗接种计划的患者，根据其特征（年龄、性别、吸烟等）和抗-HBs评分结果进行了评估。共有958人被纳入疫苗接种计划。根据风险因素评估，家庭中有慢性乙型肝炎感染患者的比例为80.6%（772/958），医护人员为9.2%（88/958），丙肝病毒阳性和慢性肝病患者为3.0%（29/958），血液透析患者为2.8%（27/958），肿瘤患者为2.1%（20/958）。69.8%（669/958）的患者接种疫苗后的免疫反应可以评估，其中只有8.1%（54/669）的患者对疫苗无反应。在无反应者中，64.8%（35/54）是血液透析和肿瘤患者。乙肝疫苗接种计划后的抗-HBs阳性率与先前研究结果相符。鉴于这种疫苗具有相当高的有效性，应主要针对包括风险人群在内的整个社区进行免疫接种。
